Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia (CLI-DI)
Evaluation of the Use of the Tissue Genesis® Icellator Cell Isolation System™ for Autologous Adipose-Derived Stromal Vascular Fraction Cells to Treat Critical Limb Ischemia
Sponsor: Tissue Genesis
This NA trial investigates Critical Limb Ischemia and is currently ongoing. Tissue Genesis leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Nov 2023 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Sep 2021 — Nov 2023 [monthly]
Active Not Recruiting NA
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
▶ Show 8 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting NA
-
Nov 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Aug 2019 — Nov 2019 [monthly]
Active Not Recruiting NA
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting NA
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Jun 2018 [monthly]
Recruiting NA
-
Feb 2017 — Oct 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tissue Genesis
- U.S. Army Medical Research and Development Command
For direct contact, visit the study record on ClinicalTrials.gov .